News

A kidney relief  drug worth €673m
Enlarge image

BusinessSwedenUK

A kidney relief drug worth €673m

10.10.2012 - British-Swedish Astra Zeneca pays Californian start-up Ardelyx up to €673m to get hold on exclusive rights for their NHE3 inhibitor programme.

After a setback this summer with an anti-obesity drug, Astra Zeneca is trying to pick up pace by getting hold on a new class of drugs. The small molecules developed by Ardelyx from Fremont (USA) target a sodium transporter on the surface of the intestinal epithelia. Astra Zeneca sees promising options for the treatment of diseases ranging from cardiovascular defects to diabetes or chronic kidney problems. On 8 October, the two companies announced a worldwide exclusive licensing agreement for Ardelyx’s NHE3 inhibitor programme worth up to €673m. The lead compound – Phase 2-ready RDX5791 – showed activity against constipation-predominant irritable bowel syndrome (IBS-C) and is also clinically tested in end-stage renal disease (ESRD) and chronic kidney disease (CKD). Under the terms of the agreement, Astra Zeneca will pay €27m up-front. Development milestones could rinse another €184m into Ardelyx’ pockets. With launch and commercialisation milestones and tiered double-digit royalties, the whole deal could yield up to €673m. Ardelyx will fund Phase II trials and Astra Zeneca further clinical development.

Aside from RDX5791, several other compounds all targeting the main transporter of sodium in the intestines, NHE3, are also subject to the deal. The effect of RDX5791 can be compared with living on a low-salt diet. Preventing the uptake of sodium ions into the body unburdens failing kidneys to eliminate excess sodium. Blocked sodium will be excreted with the faeces instead. A positive systemic effect is that no sodium will accumulate in intravascular and interstitial tissues, so hypertension and oedema formation could be effectively averted. Beyond NHE3 inhibitors, Ardelyx has three separate non-systemic preclinical compounds that are all not covered by the Astra Zeneca deal. Although targeting different molecules in the gut, they share a common property in that they are not absorbed by the gastrointestinal epithelia and are passed through the gastrointestinal tract without being altered.

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2012-04/a-kidney-relief-drug-worth-eur673m.html

BioeconomyEU

26.08.2015 In its second call for proposals, the Bio-Based Industries Joint Undertaking has earmarked €106m for the research and development of useful bio-based products.

OncologyNorway

25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.

LicensingUKSwitzerland

21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.

LicensingDenmark

18.08.2015 Danish Novo Nordisk is climbing on the antibody therapeutics bandwagon in a US$500m licensing agreement with antibody-specialist Genmab.

M&ASwitzerland

13.08.2015 Roche is stepping up its commitment in the fight against drug resistant “superbugs” with its takeover of US diagnostics play Geneweave, for up to US$425m.

M&AUK

11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.

Research and DevelopmentFranceGermany

07.08.2015 In a deal worth more than €300m, Sanofi has partnered up with German drug discovery and development company Evotec in order to develop beta cell-modulating diabetes therapies.

M&AIrelandUK

05.08.2015 Irish pharma and biotech major Shire wants to be number one in orphan diseases, and is setting out to acquire US-American Baxalta in a US$30bn deal – by any means necessary.

R&DUKSweden

04.08.2015 In a deal worth US$65m upfront, AstraZeneca is again teaming up with long-time partner Isis Pharmaceuticals Inc., this time to discover and develop RNA antisense drugs for cardiovascular, metabolic and renal diseases.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • NEUROVIVE PHARMACEUTICAL AB (S)23.00 SEK25.00%
  • BAVARIAN NORDIC (D)41.03 EUR20.85%
  • TIGENIX (B)1.02 EUR17.24%

FLOP

  • EVOCUTIS (UK)0.18 GBP-10.00%
  • BIOTIE THERAPEUTICS (FI)0.20 EUR-9.09%
  • THROMBOGENICS (B)2.90 EUR-6.15%

TOP

  • KARO BIO (S)38.10 SEK2311.4%
  • TRANSGENE (F)5.08 EUR78.2%
  • BIOTECH PHARMACON (N)12.60 NOK33.1%

FLOP

  • THROMBOGENICS (B)2.90 EUR-43.0%
  • WILEX (D)2.05 EUR-37.5%
  • BIONOR PHARMA (N)1.28 NOK-37.3%

TOP

  • KARO BIO (S)38.10 SEK4546.3%
  • ADOCIA (F)86.70 EUR432.2%
  • VERONA PHARMA (UK)4.92 GBP339.3%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-85.7%
  • BIOTEST (D)19.93 EUR-76.0%
  • NEOVACS (F)0.96 EUR-72.7%

No liability assumed, Date: 28.08.2015